Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal

被引：35

作者：

Boffa, Michael B. ^{[1
]}

Stranges, Saverio ^{[2
,3
,4
]}

Ktar, Neil ^{[2
]}

Moriarty, Patrick M. ^{[5
]}

Watts, Gerald F. ^{[6
,7
]}

Koschinsky, Marlys L. ^{[8
]}

机构：

[1] Univ Western Ontario, Schulich Sch Med & Dent, Dept Biochem, London, ON, Canada

[2] Univ Western Ontario, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada

[3] Univ Western Ontario, Schulich Sch Med & Dent, Dept Family Med, London, ON, Canada

[4] Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, Luxembourg

[5] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA

[6] Univ Western Australia, Sch Med, Perth, WA, Australia

[7] Royal Perth Hosp, Dept Cardiol, Lipid Disorders Clin, Perth, WA, Australia

[8] Univ Western Ontario, Robarts Res Inst, Schulich Sch Med & Dent, London, ON, Canada

来源：

JOURNAL OF CLINICAL LIPIDOLOGY | 2018年 / 12卷 / 06期

基金：

加拿大自然科学与工程研究理事会; 加拿大健康研究院;

关键词：

Atherothrombotic disease; Coronary heart disease; Risk factors; Epidemiology; Confounding; Clinical studies; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK; SERIES-LIPOPROTEIN; RAISED LIPOPROTEIN(A); LIPID APHERESIS; OUTCOMES; THERAPY; INTERVENTION; PREDICTION; INSIGHTS;

D O I：

10.1016/j.jacl.2018.08.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease. The principal evidence base for this comes from large population studies focusing on first atherothrombotic events. However, inconsistent findings have been reported from studies investigating the impact of elevated Lp(a) on atherothrombotic events in subjects with preexisting cardiovascular disease. This question is very important because the secondary prevention population is recommended for Lp(a) screening by some guidelines and could be an important target group for Lp(a)-lowering therapies that are currently on the horizon. In this review, we survey the secondary prevention literature as it relates to Lp(a) and identify some possible confounding factors that may underlie the inconsistent findings, such as index event bias. (C) 2018 Published by Elsevier Inc. on behalf of National Lipid Association.

引用

页码：1358 / 1366

页数：9

共 51 条

[1] Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief Report [J].

Afshar, Mehdi ;

Kamstrup, Pia R. ;

Williams, Ken ;

Sniderman, Allan D. ;

Nordestgaard, Borge G. ;

Thanassoulis, George .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (12) :2421-2423

[2] Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes) [J].

Albers, John J. ;

Slee, April ;

O'Brien, Kevin D. ;

Robinson, Jennifer G. ;

Kashyap, Moti L. ;

Kwiterovich, Peter O., Jr. ;

Xu, Ping ;

Marcovina, Santica M. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (17) :1575-1579

[3] Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options [J].

Anagnostis, Panagiotis ;

Karras, Spyridon ;

Lambrinoudaki, Irene ;

Stevenson, John C. ;

Goulis, Dimitrios G. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (12) :967-977

[4] Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers [J].

Arsenault, Benoit J. ;

Barter, Philip ;

DeMicco, David A. ;

Bao, Weihang ;

Preston, Gregory M. ;

LaRosa, John C. ;

Grundy, Scott M. ;

Deedwania, Prakash ;

Greten, Heiner ;

Wenger, Nanette K. ;

Shepherd, James ;

Waters, David D. ;

Kastelein, John J. P. .

PLOS ONE, 2014, 9 (12)

[5]

Berg K, 1997, CLIN GENET, V52, P254

[6]

Bittner V., 2018, TRIAL 18 INT S ATH T

[7] Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? [J].

Boffa, Michael B. ;

Koschinsky, Marlys L. .

JOURNAL OF LIPID RESEARCH, 2016, 57 (05) :745-757

[8] Lipoprotein(a) and Cardiovascular Risk Prediction Among Women [J].

Cook, Nancy R. ;

Mora, Samia ;

Ridker, Paul M. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (03) :287-296

[9] Index Event Bias as an Explanation for the Paradoxes of Recurrence Risk Research [J].

Dahabreh, Issa J. ;

Kent, David M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08) :822-823

[10] The renaissance of lipoprotein(a): Brave new world for preventive cardiology? [J].

Ellis, Katrina L. ;

Boffa, Michael B. ;

Sahebkar, Amirhossein ;

Koschinsky, Marlys L. ;

Watts, Gerald F. .

PROGRESS IN LIPID RESEARCH, 2017, 68 :57-82

← 1 2 3 4 5 6 →